Probiotic pill could tame COPD Flare-Ups, early trial hopes
NCT ID NCT07076290
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tests an oral probiotic called R-3750 in 27 people with mild-to-moderate COPD. The main goal is to see if it is safe and tolerable. Researchers will also check if it improves breathing and quality of life using a standard questionnaire. The study is not yet recruiting.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- R-3750 (a probiotic made from a modified bacterium, Lactococcus lactis)
- What this could lead to
- If it works, this could point toward a new way to manage COPD using a probiotic taken by mouth, potentially reducing flare-ups and improving breathing.
- What could go wrong
- This is a very early Phase 1 trial with only 27 people, focused on safety, not effectiveness. The probiotic may not show any benefit or could cause unexpected side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COPD (CHRONIC OBSTRUCTIVE PULMONARY DISEASE) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could remote rehab keep COPD patients out of the hospital?
- Blood test may curb antibiotic overuse in COPD attacks
- Smartphone and fitbit data may forecast COPD attacks
- Chest vibrations may boost lung sample collection
- Sports-Inspired balance training could help COPD patients avoid falls
- Can remote care tame COPD Flare-Ups?